REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Heavy Metal Containing (including Salts) > Polycyclo Ring System Polycyclo Ring SystemPolycyclo Ring System patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.02/01/07 - 20070027129 - Water-soluble compound A water-soluble magnetic anti-mitotic compound with a water-solubility of at least 100 micrograms per milliliter, a molecular weight of at least 150 grams per mole, a mitotic index factor of at least 10 percent, a positive magnetic susceptibility of at least 1,000×10−6 cgs, and a magnetic moment of at least ... 01/25/07 - 20070021401 - Metal complexes of n-heterocyclic carbenes as radiopharmaceuticals and antibiotics wherein Z is a heterocyclic group, and R1 and R2 are, independently or in combination, hydrogen or a C1-C12 organic group selected from the group consisting of alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, arylalkyl, alkylaryl, heterocyclic, and alkoxy groups and substituted derivatives thereof. ... 01/18/07 - 20070015742 - Porphyrin derivatives The present invention relates to a compound of formula (I): Formula (I) wherein one or two of A, B, C and D are each independently selected from S, O, Se and Te, and the remainder are N; a, b, c and d are each independently substituted or unsubstituted 5-membered heterocyclic ... 01/11/07 - 20070010506 - Methods of using nitroxides in conjuction with photosensitzers and sonosensitizers The teachings herein relate to new methods of ameliorating the negative effects of a photosensitizer or sonosensitizer in a patient using a nitroxide. ... 01/04/07 - 20070004699 - Methods and compositions for treating atheroma, tumors and other neoplastic tissues The radiation sensitization potential of a candidate compound can be screened by determine its ability to generate one or more reactive oxygen species under appropriate conditions. Compounds determined to have radiation sensitization potential are employed in methods for treating atheroma, tumors and other neoplastic tissue as well as other conditions ... 12/07/06 - 20060276444 - Porphyrin-polyamine conjugates for cancer therapy Porphyrin-polyamine conjugate compounds are disclosed which have anticancer and antitumor effects. The porphyrin moiety selectively localizes in tumors, while the polyamine moiety serves as a cytotoxic agent. Methods of making and using the porphyrin-polyamine conjugate compounds are also disclosed. ... 11/16/06 - 20060258635 - Use of a porphyrin compound for the treatment of skin fungi The present invention relates to the use of a photosensitizer compound with a specified structural formula for the treatment of a skin-borne fungus, a method of preparing a pharmaceutical composition for the treatment of a skin-borne fungus, and a method of treating a mammal suffering from a skin-borne fungus, such ... 10/26/06 - 20060241095 - Orally bioavailable low molecular weight metalloporphyrins as antioxidants The invention relates to compounds which are orally bioavailable water soluble metalloporphyrins. These compounds, e.g. represented by Structural Formula (I): wherein R1 and R2 are each independently lower alkyl, cycloalkyl, halogen substituted alkyl or substituted or unsubstituted phenyl groups, are synthetic catalytic scavengers of reactive oxygen chemical species. The invention ... 10/12/06 - 20060229284 - Enhanced occlusive effect photodynamic therapy This invention discloses methods of treating neovasculature diseases of the eye through the administration of a photosensitizing agent and subsequent exposure to light of specific wavelength sufficient to photoactivate the photosensitizing agent to occlude one or more vessels in the neovasculature for an extended period of time. Diseases treatable under ... 09/07/06 - 20060199792 - Peroxynitrite decomposition catalysts and methods of use thereof This invention provides a novel class of substituted macrocyclic metallic complexes. The complexes are useful as peroxynitrite decomposition catalysts. Pharmaceutical compositions, and methods of making and using the compounds, or a pharmaceutically acceptable salt, hydrate, prodrug, or mixture thereof are also described. ... 08/24/06 - 20060189590 - Alkaline salts of proton pump inhibitors The invention relates to alkaline salts of proton pump inhibitors and to medicaments comprising these compounds. ... 08/03/06 - 20060172986 - Polycarboxylated porphyrins and use thereof in treatment of metal toxicities Metal binding polycarboxylated porphyrins, their precursors, or cofactors in the porphyrin biosynthetic pathway, are administered to individuals determined to be subject to or predisposed to a polycarboxylated porphyrin-binding metal toxicity to increase the level of the metal-binding polycarboxylated porphyrin in the individual. ... 07/20/06 - 20060160784 - Method for treating neurologic diseases Disclosed herein are texaphyrin-metal complexes, compositions comprising such complexes, pharmaceutical formulations comprising such complexes, and methods for treating neurologic diseases, disorders and conditions and or free-radical associated diseases, disorders and conditions using such complexes, compositions and pharmaceutical formulations. ... 07/20/06 - 20060160783 - Novel omeprazole forms and related methods The invention provides: (1) novel sodium-containing omeprazole salts formed by the reaction of omeprazole and a sodium source in a crystallization solvent; (2) novel zinc-containing omeprazole salts formed by the reaction of omeprazole and a zinc source in a crystallization solvent, including salts formed by the recrystallization of a zinc ... 06/29/06 - 20060142260 - Water-soluble anionic bacteriochlorophyll derivatives and their uses The invention provides anionic water-soluble tetracyclic and pentacyclic bacteriochlorophyll derivatives (Bchls) containing at least one, preferably two or three, negatively charged groups and/or acidic groups that are converted to negatively charged groups at the physiological pH, preferably Bchls having a group COO<−>, COS<−>, SO3<−>, PO3<2−>, COOH, COSH, SO3H, and/or PO3H2 ... 06/15/06 - 20060128683 - Novel use of porphyrin derivatives The present invention is related to novel use of photopyrin compounds useful as an anticancer agent by way of reproducing singlet state oxygen radical and the inventive compounds showed potent inhibition effect on colon cancer, cervical cancer, gastric cancer, cystic cancer or lung cancer. Accordingly, the porphyrin compound of the ... 05/25/06 - 20060111335 - Photoactivated anti-viral and anti-cancer agent Bisbipyridyl rhodium (III) compound and methods for photo-induced inactivation of pathogenic contaminants in biological materials. ... 05/11/06 - 20060100190 - Motexafin lutetium phototherapy with low fluences for treating vascular inflammation Described herein are compositions, methods, therapies, strategies, techniques and processes for treating vascular inflammation in blood vessels by administering a photo-activatable compound and low light fluence in the range of about 10 to about 400 Joules/cm of illuminated length in the general vicinity of the inflammation. ... 05/11/06 - 20060100189 - Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux One aspect of the present invention relates to a method of treating or preventing pathologic sequelae of acute hyperglycemia and/or increased fatty acid flux in a subject. This method involves administering an ROS inhibitor to the subject. In addition, methods of promoting neovascularization, inhibiting oxidation or excessive release of free ... 04/27/06 - 20060089343 - Superoxide dismutase mimics for the treatment of ocular disorders and diseases The use of SOD mimics, particularly Mn(III) porphyrin complexes, for the treatment of AMD, DR, and retinal edema is disclosed. ... 02/23/06 - 20060040914 - Meso-substituted porphyrins Meso-substituted porphyrins of general formula (I) suitable for the use as photosensitising agents, in particular in photodynamnic therapy, are herein described. ... 02/23/06 - 20060040913 - Porphyrins and related compounds New porphyrins and chlorins including bacteriochlorins, for photodynamic therapy. ... 02/23/06 - 20060040912 - Compounds for pdt A tetrakis(hydroxyphenyl)chlorin, bacteriochlorin or isobacteriochlorin, derivatised at one or more of the hydroxy groups by addition reaction with a diisocyanate, diisothiocyanate or isocyanate-isothiocyanate at one isocyanate or isothiocyanate group thereof, the other isocyanate or isothiocyanate group being itself derivatised by addition reaction with the hydroxy group of an w-alkylated or ... 02/16/06 - 20060035881 - Use of targeted oxidative therapeutic formulation in endodontic treatment A pharmaceutical formulation and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethylsulfoxide (“DMSO”); a dye containing a chelated metal, such as hematoporphyrin; and an ... 01/26/06 - 20060019942 - Metal complex glycogen synthase kinase 3 inhibitors The present inventive subject matter relates to novel metal complex glycogen synthase kinase 3 inhibitors, methods for making such compounds, and methods for using such compounds for treating diseases and disorders mediated by glycogen synthase kinase 3 activity. ... 01/19/06 - 20060014732 - Use of targeted oxidative therapeutic formulation in treatment of burns A pharmaceutical formulation and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethylsulfoxide (“DMSO”); a dye containing a chelated metal, such as hematoporphyrin; and an ... 01/05/06 - 20060003983 - Photosensitizer and method for production thereof The invention relates to medicine and concerns a photosensitizer for detecting and curing tumors. The inventive photosensitizer is embodied in the form of a composition containing chlorin in the form of salt and alkali metals. The chlorin is composed of 80-90% of chlorin e6, 5-20 of purpurin 5 and the ... 01/05/06 - 20060003982 - Pyridyl-substituted porphyrin compounds and methods of use thereof The present invention relates to Pyridyl-Substituted Porphyrin Compounds, compositions comprising an effective amount of a Pyridyl-Substituted Porphyrin Compound and methods for treating or preventing injury due to exposure to a reactive species, erectile dysfunction due to surgery, lung disease, hyperoxia, neurodegenerative disease, liver disease, myocardial damage during cardioplegia, an inflammatory ... 12/08/05 - 20050272714 - Use of targeted oxidative therapeutic formulation in treatment of diabetes and obesity A pharmaceutical formulation and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethylsulfoxide (“DMSO”); a dye containing a chelated metal, such as hematoporphyrin; and an ... 12/01/05 - 20050267090 - Photoactive metal nitrosyls for blood pressure regulation and cancer therapy Disclosed are nitric oxide delivery agents and methods of their use, more specifically to photoactive compounds, which are able to perform targeted delivery of nitric oxide in vitro and in vivo and are useful for medicinal applications including, but not limited, to blood pressure regulation and cancer treatment. ... 11/24/05 - 20050261266 - Radiopharmaceutical and methods of synthesis and use thereof A novel group of apomorphine derivatives are provided that are well suited as radioimaging agents upon incorporation of radionuclides. Through reaction of D ring sites, the less reactive sites of the apomorphine A ring is modified in ways previously unattainable. ... 11/24/05 - 20050261265 - Modulating cellular senescence by amphiphysin-1 The present invention relates to nucleic acid sequences and proteins involved in senescence and particularly, to nucleic acid sequences and proteins including amphiphysin and caveolin involved in cellular senescence and their use. ... 11/10/05 - 20050250757 - Use of targeted oxidative therapeutic formulation in treatment of cancer A pharmaceutical formulation and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethylsulfoxide (“DMSO”); a dye containing a chelated metal, such as hematoporphyrin; and an ... 11/10/05 - 20050250756 - Use of targeted oxidative therapeutic formulation in treatment of age-related macular degeneration A pharmaceutical formulation and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethylsulfoxide (“DMSO”); a dye containing a chelated metal, such as hematoporphyrin; and an ... 11/10/05 - 20050250755 - Use of targeted oxidative therapeutic formulation in bone regeneration A pharmaceutical formulation and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethylsulfoxide (“DMSO”); a dye containing a chelated metal, such as hematoporphyrin; and an ... 10/20/05 - 20050234032 - Antibacterial compositions comprising metal phthalocyanine analogues The present invention relates to pharmaceutical compositions comprising metal phthalocyanine analogues of formula (I) and metal chelating compounds having a good bioavailability and enhanced photoinactivation properties against Gram negative bacteria; and to their use for in vivolex vivo applications, such as blood and blood derivatives sterilization. ... 10/13/05 - 20050227958 - Polycyclic pyridines as potassium ion channel modulators The present invention provides a genus of polycyclic pyridines that are useful as modulators of potassium ion channels. The modulators of the invention are of use in both therapeutic and diagnostic methods. ... 10/13/05 - 20050227957 - Mitochondrially targeted antioxidants The invention provides mitochondrially targeted antioxidant compounds comprising a lipophilic cation moiety covalently coupled to a glutathione peroxidase mimetic. These compounds can be used to treat patients who would benefit from the reduction of oxidative stress. ... 10/06/05 - 20050222117 - Chlorophyll and its derivatives for cancer photodynamic therapy The present invention relates to a method for treating liver cancer or oral cancer through photodynamic therapy, comprising administrating a subject in need thereof an effective amount of formula I, formula □, formula III or formula IV, which could release reactive oxygen species to inhibit the growth of cancer cells, ... 10/06/05 - 20050222116 - Porphyrin oxygen infusion preparation for increasing oxygen concentration in tumor tissue A highly safe oxygen infusion for effectively increasing an oxygen partial pressure in a hypoxic region of tumor tissues, which comprises a dispersion of an albumin clathrate compound enclosing a porphyrin metal complex, dispersed in a physiologically permissible aqueous media. ... 09/08/05 - 20050197324 - Alkylated porphyrins as pesticides acting both in the presence and absence of light An insecticidal composition comprising at least one compound of the tetrapyrrole series having at least one hydrocarbon chain at least 12 carbon atoms long as a peripheral substituent, wherein the compound of the tetrapyrrole series is selected from porphyrins, chlorins, phthalocyanines or naphthalocyanines. ... 09/01/05 - 20050192267 - Use of targeted oxidative therapeutic formulation in treatment of viral diseases A pharmaceutical formulation and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethylsulfoxide (“DMSO”); a dye containing a chelated metal, such as hematoporphyrin; and an ... 08/25/05 - 20050187207 - Immuno-adjuvant pdt treatment of metastatic tumors Immuno-adjuvant photodynamic therapy to treat and prevent metastatic cancer is effected using photosensitizers in combination with immuno-adjuvants to destroy metastatic tumor cells. ... 08/04/05 - 20050171076 - Metal complex protein kinase inhibitors This inventive subject matter relates to novel metal complex protein kinases inhibitors, methods for making such compounds, and methods for using such compounds for treating diseases and disorders mediated by kinase activity. ... 07/21/05 - 20050159401 - Texaphyrin coordination compounds and uses thereof Novel coordination polymers, their pharmaceutical formulations, useful for treating atheroma, tumors and other neoplastic tissue, as well as other conditions that are responsive to the induction of targeted oxidative stress, are disclosed. ... 07/07/05 - 20050148569 - Targeted oxidative therapeutic formulation Pharmaceutical formulation, its method of preparation, and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethyl sulfoxide; a dye containing a chelated metal, such as ... 07/07/05 - 20050148568 - Targeted oxidative therapeutic formulation Pharmaceutical formulation, its method of preparation, and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethyl sulfoxide; a dye containing a chelated metal, such as ... 07/07/05 - 20050148567 - Treatment of tattoos by photodynamic therapy The present invention relates to a photodynamic method of treating tattoos. The method comprises: (i) intradermally and/or locally delivering photosensitizer into tattooed target tissue; and (ii) irradiating the target tissue with activation energy at a wavelength appropriate to activate the photosensitizer. The present method causes the tattoo inks to fade ... 06/23/05 - 20050137180 - Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy Metallotetrapyrrolic compounds having photherapeutic properties useful in photodetection and phototherapy of target issues, particularly porphyrins and azaporphyrins that including gallium in the central pyrrolic core. Also disclosed are methods of using metallotetrapyrrolic compounds for the treatment or detection of cardiovascular disease. ... 06/16/05 - 20050130952 - Photodynamic therapy in selective cell inactivation in blood and treating immune dysfunction diseases Multiple sclerosis and rheumatoid arthritis can be treated effectively using photodynamic therapy. In this protocol, a photoactive compound is administered, allowed to distribute in the effected subject, and the subject is then irradiated to activate the photoactive compound. Alternatively, the blood of a subject to be treated can be subjected ... 06/16/05 - 20050130951 - Superoxide dismutase mimics for the treatment of optic nerve and retinal damage Methods for preventing and treating damage to the optic nerve and/or retina by the use of SOD mimics, particularly pentaazacycle Mn(II) complex SOD mimics, are disclosed. ... 06/16/05 - 20050130950 - Method for improving treatment selectivity and efficacy using intravascular photodynamic therapy A method in which photodynamic therapy is employed to inhibit, stabilize or reduce occlusions within the cardiovascular system by utilizing light within the spectral region of approximately 390 to approximately 610 nm. ... ### FreshPatents.com Support |